Circadian Influences on Chronic Kidney Disease Progression: Molecular Signaling Pathways of Melatonin and Their Therapeutic Potential
Pharmaceuticals · 18.06.2026 · 19 (6) · 952
DOI: 10.3390/ph19060952 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 18.06.2026. Verfasst von Kuo-Cheng Lu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 23142, Taiwan. Die Arbeit nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tri-Service General Hospital, National Defense Medical University.
Abstract (Originalsprache)
Chronic kidney disease (CKD) remains a leading cause of premature mortality and global disease burden, yet the molecular mechanisms underlying its progression are still incompletely understood. Accumulating evidence highlights circadian disruption as an underappreciated driver of CKD that warrants systematic re-examination. The kidney harbors an autonomous circadian oscillator, principally regulated by the CLOCK:BMAL1 transcription factor complex, which coordinates glomerular filtration, tubular electrolyte handling, blood pressure rhythmicity, inflammatory tone, and cellular repair. In CKD, retained uremic toxins, sustained oxidative stress, and persistent NF-κB activation collectively suppress this clock machinery, generating a self-reinforcing cycle of renal injury and circadian dysregulation. CKD is also accompanied by progressive attenuation of nocturnal melatonin secretion, weakening a central hormonal cue for peripheral clock entrainment and cytoprotection. Melatonin acts both as a chronobiotic and as a pleiotropic cytoprotective molecule. Through MT1/MT2 receptors, the nuclear receptor RORα, and receptor-independent antioxidant pathways, it may enhance Nrf2/HO-1 signaling, restrain NF-κB and NLRP3 inflammasome activity, suppress TGF-β1/Smad2/3-mediated fibrogenesis, preserve mitochondrial integrity, and engage SIRT1-linked clock regulation. Current clinical studies suggest that nightly melatonin supplementation can improve sleep quality and selected oxidative or circadian surrogate endpoints in hemodialysis patients; however, whether melatonin slows CKD progression or preserves renal function remains unproven. This review synthesizes the molecular interface between circadian dysregulation and CKD progression and articulates a rationale for adequately powered clinical trials evaluating melatonin as a candidate chronotherapeutic adjunct rather than an established renoprotective therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology, Department of Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 23142, Taiwan.
- School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City 24205, Taiwan.
- Division of Nephrology, Department of Internal Medicine, Fu Jen Catholic University Hospital, Fu Jen Catholic University, New Taipei City 24352, Taiwan.
- Division of Nephrology, Department of Internal Medicine, Cardinal-Tien Hospital, New Taipei City 23155, Taiwan.
- Institute of Biomedical Sciences, Academia Sinica, Taipei 115201, Taiwan.
- School of Public Health, National Defense Medical University, Taipei 114201, Taiwan.
ORCID-Profile: Kuo-Cheng Lu, Chien-Lin Lu, Yen-Sung Huang, Yu-Tien Chang, Cai-Mei Zheng, Chia-Chao Wu
Förderung
- Tri-Service General Hospital
- National Defense Medical University
Zitieren
APA
Lu, K. C., Lu, C. L., Hou, Y. C., Huang, Y. S., Chang, Y. T., Zheng, C. M., & Wu, C. C. (2026). Circadian Influences on Chronic Kidney Disease Progression: Molecular Signaling Pathways of Melatonin and Their Therapeutic Potential. Pharmaceuticals, 19(6), 952. https://doi.org/10.3390/ph19060952
Vancouver
Lu KC, Lu CL, Hou YC, Huang YS, Chang YT, Zheng CM, et al. Circadian Influences on Chronic Kidney Disease Progression: Molecular Signaling Pathways of Melatonin and Their Therapeutic Potential. Pharmaceuticals. 2026;19(6):952. doi:10.3390/ph19060952
BibTeX
@article{Lu2026,
author = {Lu, Kuo-Cheng and Lu, Chien-Lin and Hou, Yi-Chou and Huang, Yen-Sung and Chang, Yu-Tien and Zheng, Cai-Mei and Wu, Chia-Chao},
title = {Circadian Influences on Chronic Kidney Disease Progression: Molecular Signaling Pathways of Melatonin and Their Therapeutic Potential},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {6},
pages = {952},
doi = {10.3390/ph19060952}
}
EUVIMED